Posterior reversible leukoencephalopathy syndrome (PRES) is a syndrome characterized by headache, hypertension, confusion, visual disturbance, and seizures accompanied by subcortical vasogenic edema, predominantly involving the parietal and occipital lobes. The syndrome is usually described in malignant hypertension, eclampsia, renal failure, immunosuppressive, and cytotoxic chemotherapies. Bevacizumab, a monoclonal antibody that binds to the vascular endothelial growth factor (VEGF) has been linked to PRES. We carried out review of reports documenting the occurrence of PRES in patients receiving bevacizumab. This literature review was conducted by utilizing PubMed Database. If early diagnosed, PRES is reversible. We present a case of fatal PRES-associated coma induced by bevacizumab in metastatic colorectal cancer.
HincheyJChavesCAppignaniB. A reversible posterior leukoencephalopathy syndrome. N Engl J Med1996; 334: 494–500.
2.
Dedić PlavetićNRakušićZOzretićD. Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen. World J Surg Oncol2014; 12: 264–264.
3.
BartynskiWS. Posterior reversible encephalopathy syndrome: part 2. Controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol2008; 29: 1043–1049.
4.
SeetRCRabinsteinAALindellPE. Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocrit Care2011; 15: 421–427.
5.
MarinellaMAMarkertRJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J2009; 39: 826–834.
6.
BennounaJSastreJArnoldD. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol2013; 14: 29–37.
ChangYMbeoGLittmanSJ. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma. J Gastrointest Cancer2012; 43: 505–507.
9.
de PasqualeMDCastellanoAde SioL. Bevacizumab in pediatric patients: how safe is it?Anticancer Res2011; 31: 3953–3957.
10.
LevyCFOoKZFiremanF. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer2009; 52: 669–671.
11.
WangWZhaoLRLinXQ. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer. World J Gastroenterol2014; 20: 6691–6697.
12.
MiyamotoS. [Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic colorectal cancer]. Nihon Shokakibyo Gakkai Zasshi2014; 111: 743–747.
13.
GotoNMimuraJ. Gastrointestinal: bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer. J Gastroenterol Hepatol2014; 29: 895–895.
14.
LauPCPaunipagarB. Posterior reversible encephalopathy syndrome with bevacizumab. Hong Kong Med J2011; 17: 80–81.
AllenJAAdlakhaABergethonPR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol2006; 63: 1475–1478.
17.
OzcanCWongSJHariP. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med2006; 354: 980–982. discussion 980–982.
18.
DerschRStichOGollerK. Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with bevacizumab, gemcitabine and cisplatin. J Neurol2013; 260: 1406–1407.
19.
LazarusMAmundsonSBelaniR. An association between bevacizumab and recurrent posterior reversible encephalopathy syndrome in a patient presenting with deep vein thrombosis: a case report and review of the literature. Case Rep Oncol Med2012; 2012: 819546–819546.
20.
SclafaniFGiuseppeGMezynksiJ. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol2012; 30: e257–e259.
SawayaRRadwanWHammoudS. Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer. Med Oncol2014; 31: 831–831.
23.
Abbas O, Shamseddin A, Temraz S, et al. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient. BMJ Case Rep 2013; 2013. DOI: 10.1136/bcr-2012-007995.
24.
GluskerPRechtLLaneB. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med2006; 354: 980–982. discussion 980–982.
25.
LouETurnerSSumrallA. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol2011; 29: e739–e742.
26.
ArtunayOYuzbasiogluERasierR. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther2010; 26: 301–303.
27.
CaseySOSampaioRCMichelE. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol2000; 21: 1199–1206.
28.
AhnKJYouWJJeongSL. Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping. Neuroradiology2004; 46: 978–983.
29.
KimCAPrice-HillerJChuQS. Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer. Invest New Drugs2014; 32: 1036–1045.
30.
SchwartzRBJonesKMKalinaP. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol1992; 159: 379–383.
31.
De KlippelNSennesaelJLamoteJ. Cyclosporin leukoencephalopathy induced by intravenous lipid solution. Lancet1992; 339: 1114–1114.
32.
SandersTGClaymanDASanchez-RamosL. Brain in eclampsia: MR imaging with clinical correlation. Radiology1991; 180: 475–478.
33.
ImaiHOkunoNIshiharaS. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. Intern Med2012; 51: 911–915.
EdvinssonLOwmanCSjöbergNO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study. Brain Res1976; 115: 377–393.
40.
TajimaYIsonishiKKashiwabaT. Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT, and angiography. Intern Med1999; 38: 54–58.
PetrovicBDNemethAJMcCombEN. Posterior reversible encephalopathy syndrome and venous thrombosis. Radiol Clin North Am2011; 49: 63–80.
43.
Porcello MarroneLCMarroneBFPascoalTA. Posterior reversible encephalopathy syndrome associated with FOLFOX chemotherapy. Case Rep Oncol Med2013; 2013: 306983–306983.
44.
HurwitzHSainiS. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol2006; 33: 26–34.
45.
RochaJA. Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer. Anticancer Drugs2011; 22: 9–13.
46.
WeisSMChereshDA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature2005; 437: 497–504.
47.
StottVLHurrellMAAndersonTJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J2005; 35: 83–90.
48.
BermanIJMannMP. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer1980; 45: 764–766.
